Work

Changes in inpatient treatment of Clostridioides difficile infection in a US electronic health record network, 2019–2025

Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective: To describe inpatient Clostridioides difficile infection (CDI) treatment, factors associated with fidaxomicin selection, and discharge prescribing. Design: Retrospective cohort study. Setting: A US electronic health record network, 2019–2025. Patients: Adults with CDI-coded hospital admissions supported by a qualifying laboratory result or enteral treatment. Methods: We described treatment for every study year, including multiple-agent regimens and absent treatment capture. Post-June 2021 analyses compared fidaxomicin and enteral-vancomycin recipients, adjusted for patient characteristics and calendar quarter, and examined discharge prescriptions. Sensitivities considered recorded data sources, laboratory support, and recurrence ascertainment. Results: Analyses included 507,855 episodes. Initial fidaxomicin use increased from 4.4% in 2019 to 18.9% in 2025; enteral vancomycin remained predominant (76.5% in 2025). No qualifying initial treatment was captured in 15.5% and 6.3%, respectively. Among 262,592 post-update episodes meeting treatment-timing criteria, prior CDI, immunocompromising-condition codes, and transplant codes were associated with fidaxomicin selection; these associations persisted after source adjustment. Among 43,394 surviving, valid-stay episodes initially receiving fidaxomicin alone, 5,256 (12.1%) had a vancomycin-only discharge prescription; 28.4% had no qualifying outpatient prescription captured. Recorded recurrence depended on the definition and follow-up denominator. Conclusions: Fidaxomicin uptake increased, but enteral vancomycin remained predominant. Transitions from initial fidaxomicin to vancomycin at discharge highlight a care-transition question without establishing insurance-related causation. These data describe prescribing and ascertainment, not guideline effectiveness or comparative drug benefit.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,719
OpenAlex ID: W7236740592
FWCI:
Cites: 8
Cited by:
Related to: 10
Parts: 1